Last subject has completed treatment in the first part of Peptonic Medical’s phase 2b VVA study
Stockholm, 1st February 2017. Peptonic Medical AB (publ) - a company developing pharmaceuticals based on oxytocin - today announced that all of the randomized subjects of the first part of the ongoing phase 2b study (main study) now have completed the treatment and exited the study. In this study, the effect of treating menopausal and post-menopausal women suffering from vulvar and vaginal atrophy (VVA) with Peptonic Medcial’s oxytocin gel (Vagitocin®) is being investigated. A glass syringe has been used for storage and administration of the gel.In total, 161 randomized subjects